All Videos

CURIS® provides portable and fixed decontamination systems. CURIS® has revolutionized the biodecontamination world with efficacious hybrid hydrogen peroxide decontamination, which delivers a mix of vapor and micro-aerosols to each space at precisely calibrated intervals. Recent challenges in staffing for Life Sciences inspired CURIS® to help labs save time and money by creating a single system that completes multiple decontamination tasks in virtually any space, including as an integrated system for on-demand biodecontamination.

According to the International Energy Agency, COVID-19 initially lead to a “staggering” decline in energy demand and depressed energy prices. Less than two years later, we are now faced with the cost of energy at an all-time high. Rapidly growing demand and, more recently, the Russian invasion of Ukraine, are driving energy prices to unprecedented highs and challenging security of supply. It is against this backdrop of uncertainty that we are simultaneously attempting to avert climate disaster through how we generate, store, use and manage energy. Should renewable or net zero carbon targets be postponed or is this all part of the rocky road to net zero?

In this episode of Drug Digest, Pharmaceutical Technology editors, Felicity Thomas and Feliza Mirasol, examine the topic of emerging therapies in more detail, covering subjects such as the challenges of scale, the potential benefits of drug delivery innovation, importance of early analytical studies, the evolution of the regulatory landscape, and differences between regional regulatory requirements.

For decades, the power and potential of outsourcing has been viewed as a way for pharmaceutical companies to gain access to specialized domain expertise across geographic regions and achieve cost savings amidst a highly complex and diverse regulatory environment. In the face of dwindling drug pipelines, complex regulations and block-busters crossing their patent exclusivity, mature products offer a revenue stream for companies to sustain their bottom lines in a hyper-competitive global market.

Cell and gene therapies continue to expand rapidly, with an anticipated exponential growth over the next five years. This rapid growth has left an urgent need for industry scientists to gather and share lessons learned concerning bioanalytical, biomarker and regulatory strategies. This series provides insight from PPD Laboratories’ experts into a variety of cell and gene therapy (CGT) modalities in the bioanalytical community, with detailed discussions that leverage their experience with technologies and modalities within this CGT sphere.

Nanoform’s Eric Peter talks about what Nanoform showcased at AAPS 2021and what makes Nanoform’s particle engineering solutions unique.

Dr. Prasad Raje, CEO of LGM Pharma, explores the importance of investing in robust analytical testing services, how pharma companies can leverage contract analytical services to save on costs and reduce development times, and more.